Evidence map›Paper›PMID 40923024›Full record

ReviewCancer pathogenesis and therapy2025

Volatile organic compounds in exhaled breath: Applications in cancer diagnosis and predicting treatment efficacy.

Yilu Gao, Baoqing Chen, Xingyuan Cheng, Shiliang LiuD, Qiaoqiao Li, Mian Xi

Abstract readReview
In one paragraph

Review in Cancer pathogenesis and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. [Breath metabolomic characteristics of schizophrenia and their potential for auxiliary diagnosis].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yilu GaoState Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute, United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University & Chinese Academy of Sciences Ion Medical Technology Co., Guangzhou, Guangdong 510060, China.
Baoqing ChenState Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute, United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University & Chinese Academy of Sciences Ion Medical Technology Co., Guangzhou, Guangdong 510060, China.
Xingyuan ChengState Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute, United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University & Chinese Academy of Sciences Ion Medical Technology Co., Guangzhou, Guangdong 510060, China.
Shiliang LiuDState Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute, United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University & Chinese Academy of Sciences Ion Medical Technology Co., Guangzhou, Guangdong 510060, China.
Qiaoqiao LiState Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute, United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University & Chinese Academy of Sciences Ion Medical Technology Co., Guangzhou, Guangdong 510060, China.
Mian XiState Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute, United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University & Chinese Academy of Sciences Ion Medical Technology Co., Guangzhou, Guangdong 510060, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Volatile organic compounds (VOCs) are carbon-based chemicals characterized by high vapor pressure and low boiling points under standard temperature and pressure conditions. VOCs are categorized as exogenous or endogenous, depending on their source. Endogenous VOCs are metabolic byproducts eliminated via respiration. These compounds serve as indicators of human metabolic activity, reflecting differences in tumors compared to normal cell metabolism and the body's response to tumors. Examination of exhaled breath provides a noninvasive approach for assessing metabolic status by comparing VOC levels. Consequently, VOCs are increasingly studied as novel biomarkers for cancer screening, diagnosis, and treatment efficacy prediction. This review outlines VOC production mechanisms, their presence in tumor types, detection methodologies, and their implications for tumor screening, diagnosis, and prognosis. Nonetheless, challenges remain in the utilization of VOCs for cancer diagnosis and predicting treatment outcomes. Furthermore, this review discusses unresolved issues requiring attention to improve malignant tumor assessment, providing insights into their diagnosis, treatment, and prognosis.

Indexed as

DiagnosisNeoplasmsPrognosisVolatile organic compounds

Identifiers

PMID40923024
PMCPMC12414273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.